About LigaChemBio
LigaChemBio is a publicly listed company based in Daejeon (South Korea) founded in 2006. Therapeutics for cancer treatment are developed using antibody-drug combinations. Its chief executive, as recorded, is Yong Ju Kim. Its website ligachembio.com draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Founded in 2006 in Daejeon, South Korea, anticancer therapeutics are developed within the biotechnology sector. Antibody-drug conjugates are created to leverage antibody selectivity alongside synthetic drug efficacy. A pipeline of candidates, such as LCB14, LCB84, and LCB71, is advanced for various cancer indications. Operations focus on innovative drug combinations to address unmet needs in oncology.
- Headquarters Daejeon, South Korea
- Stage Public
- SectorsHealthcare
- Website ligachembio.com
- Social LinkedIn
- Legal Name Ligachem Biosciences Inc.
- Annual Revenue$98.01 M (USD)12.43as on Dec 31, 2025
- Net Profit-$51.43 M (USD)-1052.27as on Dec 31, 2025
- EBITDA-$69.29 M (USD)-523.64as on Dec 31, 2025
People of LigaChemBio
1 people are tracked at LigaChemBio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Yong Ju Kim | CEO | Leadership |
Complete people profiles for LigaChemBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of LigaChemBio
LigaChemBio is a publicly listed company on the KRX with ticker symbol 141080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 May 2013
- Listed onKRX: 141080
- Listed entityLigaChem Biosciences Inc.
- Exchange sectorHealth technology
- ISINKR7141080002
- Share price66,100.00 KRW (+0.92% on the day) · 2026-10-14
- Market capitalisation2,413,703,134,537.00 KRW
- EPS (diluted, trailing year)-4,887.49 KRW
- Volume (last session)196,856
Financials of LigaChemBio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 141.55B KRW | -74.28B KRW | -100.07B KRW |
| 2024 | 125.90B KRW | 7.80B KRW | -16.05B KRW |
| 2023 | 34.15B KRW | -73.70B KRW | -76.92B KRW |
| 2022 | 33.41B KRW | -45.09B KRW | -50.92B KRW |
| 2021 | 32.16B KRW | -23.39B KRW | -33.48B KRW |
Detailed financial statements for LigaChemBio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of LigaChemBio
The website of LigaChemBio (ligachembio.com) receives about 11.1K visits a month.
- Monthly visits11.1K
▲ 15.8% vs previous month
Websites whose visitors overlap most with LigaChemBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| legochembio.com | 100% | #4,175,811 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ligachembio
Complete news archive for LigaChemBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LigaChemBio
LigaChemBio was founded in 2006.
LigaChemBio is headquartered in Daejeon, South Korea.
Yong Ju Kim is the CEO of LigaChemBio, as recorded in our data.
Annual revenue of LigaChemBio is $98.01M as on Dec 31, 2025.
Founded in 2006 in Daejeon, South Korea, anticancer therapeutics are developed within the biotechnology sector. Antibody-drug conjugates are created to leverage antibody selectivity alongside synthetic drug efficacy. A pipeline of candidates, such as LCB14, LCB84, and LCB71, is advanced for various cancer indications. Operations focus on innovative drug combinations to address unmet needs in oncology.
Yes, LigaChemBio is publicly traded on KRX under the ticker symbol 141080.